OSI/Roche warn of GI, skin and eye problems with Tarceva
12 May 2009
Sue Sutter
Please Login to read the full article.
12 May 2009
Sue Sutter
sue.sutter@informa.com
OSI Pharmaceuticals/ Roche (formerly Genentech) are warning doctors about the risk of gastrointestinal perforations, serious skin reactions and ocular disorders with the EGFR-targeted oncologic Tarceva (erlotinib).
The companies recently issued a "Dear Doctor" letter about new US label warnings...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Tragara sees peachy Capoxigem future even as APRiCOT trial fails overall in NSCLC
- Astellas mulls darexaban alliances as pipeline moves forward
- Easing of Japanese Tarceva restrictions in NSCLC set to raise pressure on Iressa
- CHMP extensions for Roche's Tarceva, Novartis' Afinitor and Wyeth's Enbrel
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
